TrialThe New England journal of medicine2026

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.

Sara M Tolaney et al.PubMed ↗Publisher ↗

No numbers read from the abstract.